predict the effectiveness of medication through blood proteins
Personalized medicine—that is, the customization of medical treatment according to the characteristics of individual patients—is a very promising field. And a Montreal company, Caprion Proteomics, is considered a leader in this cutting edge sector. The SME, headed by Martin LeBlanc, is the leading provider of proteomics-based (the study of proteins in cells, tissues, and organs) services to the pharmaceutical and biotechnology industries. The unique proteomics discovery platform developed by Caprion, CellCarta, profiles proteins in the blood that can play a role in predicting the effectiveness of a medication. This innovation has made Caprion Proteomics an industry leader: it has been providing proteomics biomarker and target identification services since 2002, and has performed multiple large-scale biomarker discovery and validation projects for over 20 major pharmaceutical industry clients. Caprion is also making use of CellCarta to discover and develop its own range of diagnostic products in the areas of infection, cancer, and diabetes. To finance this development, Caprion has already been awarded five contracts, with a cumulative value of $23 million, from the pharmaceutical industry, as well as the American, Canadian, and Quebec governments.
